Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Dominique Bron is Professor of Hematology at the Free University of Brussels (ULB) and Head of the department of clinical and experimental hematology at the Institut Jules Bordet, Cancer center of the ULB, in Brussels, Belgium.
Professor Bron graduated in internal medicine/hematology in 1984 and received her PhD in 1990. During her training in internal medicine, she acquired particular expertise in onco-hematology and transplantation after two postgraduate fellowships with Professor H. Kaplan, Stanford University, California, USA, and Professor D. Thomas, director of the Transplant Unit of Seattle, Washington, USA.
Professor Bron contributed to the development of the research in the field of chronic lymphoid leukemia and marrow microenvironment.
Professor Bron is a member of the American Society of Hematology, the International Society of Experimental Hematology, the EBMT, the EORTC, and past board member of the EHA. She was the president of the BHS (Belgian Hematology Society) for three years. During that period, she organized the national course of excellence in Hematology and was involved in a unique program concerning harmonization of teaching hematology (H-NET/EU Program). She is also member of the Royal Academy of Medicine in Belgium.
Professor Bron is the author of more than 250 scientific publications, and more than 500 communications in national and international congresses. She is currently heading an EHA scientific working group on “Aging and Hematology” and also works as an Honorary Professor at the University of Ho Chi Minh, Vietnam. She is deeply involved in outreach programs for education and research in Vietnam.
Professor Bron is also concerned with ethical issues related to cancer patients and stem cell research, and on a national level being President of the ethical review board at the Institut Jules Bordet for more than 20 years.
Professor Bron is, with her team, involved in several clinical trials (phase II, III, IV) in hematologic malignancies.
Christian Chabannon, MD, PhD, is board certified in Hematology and Medical Oncology. He is a Professor of Medicine in Cell Biology at Aix-Marseille Université School of Medicine in Marseille, France. He is a full member at Institut Paoli-Calmettes Comprehensive Cancer Center in Marseille as well, where he heads the “Centre de Thérapie Cellulaire” that includes the hematopoietic cell collection and cell processing facilities.
Since 2005, he coordinates the Marseille “Centre d’Investigations Cliniques en Biothérapies”, Inserm CBT-1409 that brings together investigators from both the University Hospital (AP-HM), the Institut Paoli-Calmettes and several research groups in the metropolitan area that share interest in the development of innovative therapies manufactured from human cells and tissues. Christian Chabannon led the onboarding process to bring approved and commercially manufactured CAR-T cells to patients taken care off at Institut Paoli-Calmettes.
Christian Chabannon is a member of several professional associations including the American Society of Hematology (ASH), the European society for Blood and Marrow Transplantation (EBMT), The European Hematology Association (EHA), the European Society for Medical Oncology (ESMO), The International Society for Cell and gene Therapy (ISCT), the “Société Francophone de Greffe de Moelle et de Thérapie Cellulaire” (SFGM-TC). Within EBMT, he chaired the JACIE Accreditation Committee, and is now Chair of the Cellular Therapy & Immunobiology Working Party (CTIWP), where he designed together with other WP members the Cellular Therapy Form now part of the EBMT registry that allows to register patients treated with CAR-T Cells and capture their follow-up, a key undertaking in the context of Post-Authorization Safety Studies (PASS) and Post-Authorization Efficacy Studies (PAES). He also contributed to initiate educational activities focusing on CAR-T cells administration and management.
Since he joined Institut Paoli-Calmettes, Christian Chabannon has been an investigator in many preclinical and clinical trials aiming at the evaluation of innovative modalities of autologous and allogeneic hematopoietic cell transplantation, as well as of academia- or industry-manufactured Advanced Therapy Medicinal Products with applications in the field of hematology and medical oncology.
Jean A. Klastersky
Professor Klastersky was Head of the Department of Medicine at the Institut Jules Bordet in Brussels, Belgium, and Professor of Medicine, Medical Oncology and Physical Diagnosis at the Université Libre de Bruxelles, Belgium, from 1977. He retired from these positions in 2005. Currently, he is the coordinator of the “Programme des Soins Oncologiques” for the Public Hospitals in Brussels and consultant in medical oncology at the Institut Jules Bordet, Belgium.
Professor Klastersky was an intern and resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965, where he gained his MD (Docteur en Médecine, Chirurgie et Accouchements). From 1967 to 1968, he was Chief-Resident at Boston City Hospital, USA, and then a Research Fellow and Assistant in Medicine at Thorndike Memorial Laboratory Harvard Medical School, USA. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970, before taking up the position of Head of the Department of Medicine in 1977.
Professor Klastersky was a founder member of the European Lung Cancer Working Party and was President from 1978 until 2003. He was President (and founder member) of the International EORTC Antimicrobial Therapy Project Group between 1979 and 1987 and the Group's Secretary General from 1987 to 2000. He was President (and founder member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000.
He has been Visiting Professor of Medical Oncology at the Charles University in Prague, Czech Republic, since 1994.
Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Diseases Society of America, the International Association for the Study of Lung Cancer, the “Royale Académie de Médecine” of Belgium and various other international and national medical and/or oncological societies.
Professor Klastersky is the author of over 400 original articles, nearly 400 review articles and 17 scientific books.
He is the Editor of Current Opinion in Oncology.
Professor Ahmad Awada studied medicine at the Université Libre de Bruxelles (ULB), Belgium. He specialized in internal medicine and medical oncology at Jules Bordet Institute, in Brussels, until 1992 (“La plus grande distinction”). During his specialization, he also undertook training in the clinical development of new therapies and new anticancer drugs.
To deepen his training, he stayed in the Netherlands at the New Drug Development Office, Free University, Amsterdam and in San Antonio, USA at Institute for Drug Development. He focused on the clinical development of new anticancer agents.
Returning from the USA at the beginning of 1994, Doctor Awada became Assistant Head of Medical Oncology Clinic, and Head of the New Drugs Development Unit at Jules Bordet Institute, Brussels. Since April 2005, he has been the Head of the Medical Oncology Clinic. In addition to this, on 1st March 2011, Dr Awada was made Associate Head of the Medicine Department. More recently in July 2017, Dr Awada was appointed Head of Oncology Medicine Department at Jules Bordet Institute. He has an important clinical activity in the treatment of solid tumors. Doctor Awada took an active part in the development of new anticancer drugs, some of them already widely used.
Thanks to the recent progress in molecular biology, many new drugs are now studied to block the process of carcinogenesis (cancer cell and microenvironment). Those are the molecular-targeted therapies, a subject studied extensively in clinical research by Doctor Awada which was the basis for the thesis obtained from the ULB, Brussels, in 2004.
Professor Awada's aim, as far as research is concerned, is to look for new active anticancer drugs in solid tumors (new cytotoxics and antibody drugs conjugates, molecular targeted therapies and immunotherapy), and to individualize the treatments of cancer patients.
Steven T. Rosen
Steven T. Rosen, MD, FACP, FASCO, is the provost, chief scientific officer, and director of the Comprehensive Cancer Center and the Beckman Research Institute, Irell & Manella Cancer Center Director's Distinguished Chair for the City of Hope in Duarte, California. Following his graduation with distinction from Northwestern University Medical School's Six-Year Honors Program in Chicago, Illinois, Dr Rosen completed his residency in internal medicine at Northwestern and a fellowship in medical oncology at the National Cancer Institute in Maryland, USA. He served as the Director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine from 1989–2014.
Dr Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies. He has received funding from the National Cancer Institute (NCI), American Cancer Society, Leukemia and Lymphoma Society (LLS), Multiple Myeloma Research Foundation, and Rising Tide Foundation. Dr Rosen has received numerous grants, awards and contracts and has published more than 400 scientific papers. He is editor-in-chief of Cancer Treatment and Research. Dr Rosen is the chair of the Medical Science Committee of the LLS and serves on its Board. He also serves on the Board of American Society of Clinical Oncology's Conquer Cancer Foundation. Dr Rosen has been an advisor to more than two dozen NCI Comprehensive Cancer Centers.
He was the recipient of Northwestern University Medical School's Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996), recognition from the Woman's Board of Northwestern Memorial Hospital for Compassionate Care (1996), and Israel Cancer Research Fund, Man of Distinction Award (2011), and Lifetime Achievement Award (2015). Best Doctors in Chicago and Los Angeles. American Institute for Medical and Biological Engineering (AIMBE's) College of Fellows (2017). Association of American Physicians (AAP) (2019).